Valuation: Biodesix, Inc.

Market Cap 245M 220M 202M 183M 342M 23.3B 349M 2.41B 968M 12.26B 921M 901M 38.65B P/E 2026 *
-8.71x
P/E 2027 * -13.9x
Enterprise Value 245M 220M 202M 183M 342M 23.3B 349M 2.41B 968M 12.26B 921M 901M 38.65B EV / Sales 2026 *
2.19x
EV / Sales 2027 * 1.82x
Free-Float
54.99%
Yield 2026 *
-
Yield 2027 * -
1 day-5.93%
1 week+9.80%
1 month-22.04%
3 months+9.69%
6 months+111.79%
Current year+241.99%
1 week 20.11
Extreme 20.11
25.06
1 month 20.11
Extreme 20.11
30
Current year 5.26
Extreme 5.26
31.97
1 year 5.26
Extreme 5.26
31.97
3 years 3.44
Extreme 3.436
44.2
5 years 3.44
Extreme 3.436
166.87
10 years 3.44
Extreme 3.436
639.8
Manager TitleAgeSince
Chief Executive Officer 54 2019-12-31
Director of Finance/CFO 46 2017-03-31
Chief Tech/Sci/R&D Officer - 2015-12-31
Director TitleAgeSince
Chairman 79 2020-09-13
Director/Board Member 53 2011-12-31
Director/Board Member 59 2020-03-31
Date Insider Type Main position Quantity % Market Cap. Importance
9/30/26 Exercice

Chairman

2,720 0.0340%
8/12/26 Buy 15,000 0.1422%
8/11/26 Buy 13,700 0.1298%
Change 5-day change 1-year change 3-year change Capi.($)
-5.93%+9.80%+240.48%-18.12% 245M
-0.09%-3.44%+15.48%+30.78% 115B
-1.02%+0.89%+2.94%+109.25% 98.85B
-4.98%+2.56%+108.26%+949.66% 59.72B
+1.44%+1.95%-6.04%+93.89% 30.06B
-1.84%+9.86%+42.30%+80.94% 29.34B
-0.43%+4.11%+43.12%+93.56% 27.71B
+0.99%+1.79%+32.33%+408.85% 21.75B
-1.58%+3.86%-19.91%-13.49% 20.66B
-.--%-0.63%-4.85%+30.83% 17.09B
Average -1.34%+3.24%+45.41%+176.61% 42.08B
Weighted average by Cap. -1.05%+1.07%+26.29%+209.08%

Financials

2026 *2027 *
Net sales 112M 100M 92.12M 83.46M 156M 10.62B 159M 1.1B 441M 5.58B 420M 411M 17.61B 135M 121M 111M 100M 188M 12.78B 191M 1.32B 531M 6.72B 505M 495M 21.21B
Net income -27.51M -24.64M -22.66M -20.54M -38.39M -2.61B -39.11M -270M -108M -1.37B -103M -101M -4.33B -19.47M -17.44M -16.04M -14.54M -27.17M -1.85B -27.68M -191M -76.8M -973M -73.08M -71.53M -3.07B
Net Debt - -
Projected Income Statement - Annual - Biodesix, Inc.
Logo Biodesix, Inc.
Biodesix, Inc. is a diagnostic solutions company. The Company's business includes Biodesix Lung Diagnostic Testing and Biodesix Development Services. Its Biodesix Lung Diagnostic Testing provides lung diagnostic testing services for healthcare providers through five blood-based tests. Its Biodesix Development Services supports global biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that enable the development of diagnostic tests, tools, and therapeutics. The Company offers Nodify Lung tests and IQLung tests that assess cancer risk and provide treatment guidance following a lung cancer diagnosis. The Nodify Lung tests include Nodify CDT and Nodify XL2 tests, which evaluate the risk of lung cancer in lung nodules. The GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests are used in the diagnosis of lung cancer to detect tumor mutations and assess the patient’s immune system status.
Employees
334
Date Price Change Volume
26-10-30 US$23.26 -5.93% 67,248
26-10-29 US$24.72 +8.14% 70,235
26-10-28 US$22.86 +4.15% 101,350
26-10-27 US$21.95 +3.25% 141,669
26-10-26 US$21.26 +0.38% 60,944
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Biodesix, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
23.26USD
Average target price
39.00USD
Spread / Average Target
+67.71%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Biodesix, Inc.
  1. Stock Market
  2. Stocks
  3. BDSX Stock